This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Aetiology

Authoring team

Aetiology is multifactorial. Increased risk of BPH is seen with advancing age, endogenous androgens and prostate volume, black men (while Asian men have a lower risk) (1).

The hormonal theory postulates that nodular hyperplasia is due to an increased oestrogen to testosterone ratio which is associated with ageing. The oestrogen enhances the expression of receptors for dihydrotestosterone, derived from plasma testosterone, which mediates prostatic growth.

In support of this theory:

  • nodular hyperplasia occurs only in the presence of an intact testis
  • levels of plasma testosterone are similar in those with and without the disease, and decline after the age of 60 years (2)

The neoplastic theory proposes that enlargement is due to a fibromyoadenoma i.e. a benign neoplasm of fibrous, muscle, and glandular tissue

As the size of the prostate does not linearly correlate with clinical features, enhanced prostatic smooth muscle tone and an irritable bladder wall have been postulated as features which trigger symptoms.

Reference:

  1. Mangera A, Chapple C. Clinical Review: Benign prostatic hyperplasia. GPOnline 2012
  2. Drug and Therapeutics Bulletin (1995). 33(3): 19-21

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.